Padcev plus Keytruda shows superior response and survival rates in first-line metastatic urothelial carcinoma treatment compared to chemotherapy. Padcev monotherapy provides clinical benefits in later ...

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to chemotherapy for patients ...

While cohort H looked at Padcev as a monotherapy, checkpoint inhibitors like Merck & Co's Keytruda (pembrolizumab) and Merck KGaA/Pfizer's Bavencio (avelumab) have already shown activity in the ...